#1 Clinical Trials Search in Europe

Glutenin

A clinical trial is underway to investigate the effectiveness of a drug called Glutenin, also known as FX06, in treating patients with Acute Respiratory Distress Syndrome (ARDS). This study aims to determine if FX06 can improve the severity of ARDS and help patients breathe without assistance more quickly. The trial will compare FX06 to a placebo and examine various aspects of patient recovery, including lung function, inflammation, and overall survival.

Table of Contents

What is GLUTENIN (FX06)?

GLUTENIN, also known as FX06, is a new medication being studied for the treatment of Acute Respiratory Distress Syndrome (ARDS). It is a protein-based drug developed by F4PHARMA GMBH[1]. GLUTENIN is given as a solution for injection directly into the bloodstream (intravenously)[1].

What is Acute Respiratory Distress Syndrome (ARDS)?

Acute Respiratory Distress Syndrome (ARDS) is a serious lung condition that causes difficulty breathing. It occurs when fluid builds up in the tiny air sacs in your lungs, preventing them from filling with enough air. This makes it hard for your body to get the oxygen it needs. ARDS can be life-threatening and often requires treatment in an intensive care unit (ICU)[1].

How GLUTENIN (FX06) May Help ARDS Patients

While the exact mechanism is still being studied, researchers believe that GLUTENIN (FX06) may help improve the condition of patients with ARDS in several ways:

  • Reducing inflammation in the lungs
  • Improving oxygen levels in the blood
  • Helping patients breathe on their own more quickly
  • Potentially shortening the time spent in the hospital or ICU

These potential benefits are being investigated in the current clinical trial[1].

Current Clinical Trial for GLUTENIN (FX06)

A clinical trial called “Ixion 2.0” is currently underway to study the effects of GLUTENIN (FX06) in patients with ARDS. This is a Phase II clinical trial, which means it’s designed to test how well the drug works and to further evaluate its safety[1].

The main goal of this trial is to see if patients who receive GLUTENIN (FX06) can breathe on their own without assistance more quickly than those who receive a placebo (a substance with no active medication)[1].

Who Can Participate in the Trial?

The trial is looking for specific types of patients to participate. Some key criteria include:

  • Adults aged 18 or older
  • Patients with mild to moderate ARDS
  • Patients diagnosed with ARDS within the last 48 hours

However, some people may not be able to participate, such as:

  • Patients with severe ARDS
  • Pregnant or breastfeeding women
  • People with certain other serious medical conditions

A doctor involved in the study will carefully review each person’s medical history to determine if they’re eligible to participate[1].

What to Expect During the Trial

If a patient participates in the trial, they may receive either GLUTENIN (FX06) or a placebo. The medication is given through an intravenous injection, which means it’s delivered directly into the bloodstream through a vein[1].

Throughout the study, doctors will closely monitor various aspects of the patient’s health, including:

  • Lung function: How well the lungs are working and how much oxygen is in the blood
  • Inflammation levels in the body
  • How quickly the patient can start breathing on their own
  • How long the patient needs to stay in the hospital or ICU
  • Any side effects or safety concerns

These observations will help researchers understand how well GLUTENIN (FX06) works and if it’s safe for patients with ARDS[1].

Potential Benefits of GLUTENIN (FX06)

While it’s important to remember that GLUTENIN (FX06) is still being studied and its effects are not yet fully known, researchers hope it may offer several benefits for ARDS patients:

  • Faster recovery: Patients might be able to breathe on their own more quickly
  • Reduced inflammation: This could help improve overall lung function
  • Shorter hospital stays: Patients might be able to leave the hospital or ICU sooner
  • Improved survival rates: While this is still being studied, researchers hope GLUTENIN (FX06) might help reduce mortality in ARDS patients

It’s crucial to note that these potential benefits are still being investigated, and more research is needed to confirm the effectiveness and safety of GLUTENIN (FX06) for ARDS patients[1].

Aspect Details
Drug Name Glutenin (FX06)
Condition Treated Acute Respiratory Distress Syndrome (ARDS)
Trial Phase Phase II
Primary Objective Measure time to unassisted breathing within 28 days
Secondary Objectives Disease progression, lung function, inflammation, survival, hospital stay duration
Administration Method Intravenous injection
Maximum Daily Dose 400 mg
Maximum Total Dose 2000 mg
Treatment Duration Up to 5 days

FAQ

  • What is Acute Respiratory Distress Syndrome (ARDS)? ARDS is a serious lung condition where fluid builds up in the air sacs, making it difficult for patients to breathe. It often requires mechanical ventilation or other forms of breathing support.
  • What is the main goal of this clinical trial? The main goal is to see if patients receiving FX06 can breathe without assistance sooner than those receiving a placebo, within 28 days of starting treatment.
  • Who can participate in this clinical trial? The trial is open to adults (18 years or older) with mild to moderate ARDS, diagnosed within the last 48 hours. Patients must not have severe ARDS or other significant uncontrolled health conditions.
  • How is FX06 given to patients? FX06 is given as an intravenous injection, which means it's administered directly into the patient's bloodstream.
  • What will researchers measure during the trial? Researchers will look at various factors including lung function, inflammation markers in the blood, survival rates, time spent in the hospital and ICU, and overall safety of the treatment.

Ongoing Clinical Trials on Glutenin

  • Study on FX06 for Improving Acute Respiratory Distress Syndrome in Patients

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Germany Lithuania Romania Spain

Glossary

  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition where fluid builds up in the air sacs, making it difficult to breathe and often requiring mechanical ventilation.
  • FX06: The study name for the drug Glutenin, which is being tested as a potential treatment for ARDS.
  • Unassisted Breathing (UAB): The ability to breathe without the help of mechanical ventilation or other breathing support devices.
  • Placebo: A substance with no active medical effects, used as a control in testing new drugs.
  • Horowitz Index: A measure of lung function that compares the oxygen level in the blood to the amount of oxygen being given to the patient.
  • Systemic Inflammation: A widespread inflammatory response in the body, often measured by various blood markers.
  • Capillary Refill Time: A test that measures how quickly blood returns to capillaries after they've been pressed, indicating circulation health.
  • Intensive Care Unit (ICU): A specialized hospital unit providing intensive care and close monitoring for critically ill patients.
  • Intravenous Injection: A method of administering medication directly into a vein.
  • Berlin Definition of ARDS: A set of criteria used to diagnose and classify the severity of ARDS in patients.

References

  1. http://clinicaltrials.eu/trial/study-on-fx06-for-improving-acute-respiratory-distress-syndrome-in-patients/